Protozoan parasites in the genus Leishmania are obligate intracellular pathogens that can cause a wide spectrum of diseases, ranging from benign cutaneous lesions to life-threatening visceral infections. Leishmania spp. exhibit a dimorphic life cycle, in which parasites are transmitted by a sand fly vector as flagellated promastigotes and reside within mammalian macrophages (Ms) as amastigotes. The fate of intracellular amastigotes depends largely on the activation status of Ms, which is greatly influenced by various cytokines and chemokines (19, 34, 35) . In general, Th1 cytokines (e.g., gamma interferon [IFN-␥] and tumor necrosis factor alpha [TNF-␣]) induce classical M activation, leading to an upregulation of inducible NO synthase (iNOS) and production of leishmaniacidal nitric oxide (NO) (24, 32) . Th2 cytokines (e.g., interleukin-4 and IL-10), on the other hand, induce arginase activation (19) , which is involved in the production of polyamines needed for parasite proliferation (17) .
Due to the critical role of iNOS in inducing parasite killing and of arginase in promoting parasite proliferation, it is not surprising that the activities of iNOS and arginase are tightly regulated, displaying counter-regulatory mechanisms on one another. For example, N -hydroxy-L-arginine (LOHA), an intermediate product in the iNOS pathway, is known to strongly inhibit arginase function (16) . Conversely, arginase can reduce iNOS activity by competitively utilizing L-arginine, a common substrate for both the iNOS and the arginase pathways (13) . The activities of iNOS and arginase are also dependent on L-arginine availability. It has been shown that L-arginine from the extracellular milieu is required for iNOS-dependent NO synthesis (31) . A similar association of L-arginine transport was also documented for arginase activity, as suggested by a significant reduction of L-arginine conversion to L-ornithine and polyamines in Ms lacking an L-arginine transporter (39) . These studies suggest that L-arginine transport from the extracellular milieu is important in providing factors needed for parasite growth and killing within the host cells.
Several L-arginine transport systems, including systems y ϩ , B oϩ , b oϩ , and y ϩ L, have been documented (36) . The basal level of L-arginine is maintained primarily through the y ϩ L system in nonactivated Ms, while transport through the y ϩ system increases significantly in activated Ms (39) . The cationic amino acid transporter family (CAT) belongs to the y ϩ system transporter family that includes four members, CAT-1 to CAT-4, encoded by the Slc7A1 to -4 genes, respectively (36) . While the first three members (CAT-1, -2, and -3) transport cationic amino acids such as L-arginine, the function of CAT-4 is unclear (36) . CAT-1 is widely distributed in various tissues except in adult livers (20) , while CAT-3 is expressed only in the brain (36) . CAT-2 is expressed in two splice variants, with CAT-2A being constitutively expressed in the liver and muscle cells (5) and CAT-2B being induced by cytokines in many cell types, including Ms (25) . The expression of CAT-2B in Ms is of particular interest in Leishmania research due to its ability to provide substrates for efficient iNOS and arginase activities, during M classical activation (via IFN-␥ ϩ lipopolysaccharide [LPS] ) and alternative activation (via IL-4 ϩ IL-10), respectively (39) . Despite this crucial role of CAT-2B in the regula-tion of iNOS and arginase activities (25) , there is limited knowledge on how this transporter may directly influence the outcome of Leishmania infection.
Although it is important to examine L-arginine transport of Leishmania-infected cells, it is also crucial to understand the pathways by which L-arginine is utilized. Beside L-arginine usage by iNOS in classically activated Ms (15, 23) and by arginase in alternatively activated Ms (17) , it has been reported that in vitro cultured Leishmania parasites can also directly acquire and utilize L-arginine from the extracellular milieu for polyamine synthesis (18, 30) . Although the exact pathways by which Leishmania can access the L-arginine pool within the host Ms remain unclear, it is possible that cellular L-arginine transport may be directed toward the parasites residing within the cells.
In our previous study, we reported that, instead of facilitating parasite killing, IFN-␥ treatment actually increases the number of L. amazonensis amastigotes in murine Ms, independently of IL-10 and transforming growth factor ␤ (27) . Since the understanding of mechanisms underlying IFN-␥-mediated parasite growth enhancement may provide new insights into treatment and vaccine strategies against New World cutaneous leishmaniasis, we sought to examine the potential mechanisms for this phenomenon with a focus on L-arginine transport and L-arginine usage. In the present study, we found that infection with L. amazonensis amastigotes in the presence of IFN-␥ led to an upregulation of the Slc7A2 gene in infected Ms. Moreover, L-arginine availability appeared to be a key regulator of IFN-␥-mediated amastigote growth enhancement, as evidenced by reduced parasite burdens in the presence of the nonmetabolized L-arginine analogues L-NMMA and L-SDMA. Using Ms from CAT-2 knockout (KO) mice, we further demonstrated a requirement of mouse CAT-2B (mCAT-2B) in IFN-␥-mediated parasite growth enhancement. Together, our data strongly suggest the involvement of mCAT-2B and Larginine availability in IFN-␥-mediated parasite growth enhancement. Since IFN-␥-treated, L. amazonensis-infected Ms lack detectable activities for iNOS or arginase, we proposed that IFN-␥-mediated parasite growth enhancement was likely due to a novel L-arginine metabolic pathway independent of iNOS or arginase. The possibility of direct L-arginine usage by the parasites is discussed.
MATERIALS AND METHODS
Mice. Female BALB/c and C57BL/6 mice (Harlan, Indianapolis, IN), as well as CAT-2 KO mice (6 weeks to 6 months old) on the C57BL/6 background (25, 39) , were used in the present study. All mice were maintained under specificpathogen-free conditions. All protocols were approved by the Animal Care and Use Committee of the University of Texas Medical Branch (Galveston, TX).
Reagents. Recombinant mouse IFN-␥ and IL-4 were purchased from Leinco Technologies (St. Louis, MO). LPS from Salmonella enterica serovar Typhimurium, N G -methyl-L-arginine (L-NMMA), N -nitro-L-arginine methyl ester hydrochloride (L-NAME), and L-arginine were purchased from Sigma.
Parasites. L. amazonensis (RAT/BA/74/LV78) clone 12-1 (a gift from KwangPoo Chang, Department of Microbiology and Immunology, Chicago Medical School) was maintained as axenic amastigotes in complete Grace's insect cell culture medium (Invitrogen/Gibco, Carlsbad, CA), supplemented with 20% fetal bovine serum (pH 5.0; HyClone, Logan, UT) at 33°C (10) . Lesion-derived amastigotes of L. amazonensis (MHOM/BR/77/LTB0016) obtained from foot tissues of infected BALB/c mice were cultured in Schneider's Drosophila media (Invitrogen/Gibco) supplemented with 20% fetal bovine serum (pH 5.0) at 33°C for 2 days prior to use (27) . Lesion-derived amastigotes remained in the amastigote form under these culture conditions. L. mexicana (TG) axenic amastigotes were obtained from a patient in 2002 (37) and were maintained as the amastigote form in Schneider's Drosophila media (pH 5.0) at 33°C. pM cultures. Mice were injected intraperitoneally with 2 ml of 3% Brewer's thioglycolate broth for 5 to 7 days. Peritoneal M (pMs) were harvested using cold 2 mM EDTA in phosphate-buffered saline (PBS) solution and then plated at a concentration of 3 ϫ 10 5 cells/well/ml in 24-well tissue culture plates for the determination of infection or at a concentration of 10 5 cells/well/200 l in 96-well tissue culture plates for the arginase activity assays. pM stimulation and parasite infection. pMs were either left untreated or were treated for 4 h with 20 ng of IFN-␥/ml alone, together with 10 ng of LPS/ml, or with 20 ng of IL-4/ml alone. As previously reported, IFN-␥ at the concentration of 20 ng/ml was found to be the optimal dose, yielding high parasite growth enhancement (27) . After incubation at 33°C for the indicated times, cells were infected with L. amazonensis amastigotes at 2:1 parasite/cell ratios. The culture plates were spun at 100 ϫ g for 5 min to synchronize the binding of amastigotes to pMs. The cultures were maintained at 33°C for an indicated additional time prior to each specific assay.
Determination of parasite burden in infected pMs. The number of amastigotes per well in infected pMs was determined as previously described (27) . Briefly, pMs in 24-well plates were incubated for approximately 10 to 15 min with 200 l of a sodium dodecyl sulfate-PBS solution (0.01% [wt/vol]) to release the intracellular amastigotes. The lysis process was monitored visually to verify adequate release of intact parasites. The reaction was stopped by adding 0.8 ml of PBS per well, the released parasites were resuspended thoroughly by repeated pipetting, and the parasites were counted by using a hemocytometer.
One-step real-time reverse transcription-PCR (RT-PCR). Applied Biosystems (Foster City, CA) Assays-by-Design and Assays-on-Demand 20ϫ assay mixes of primers and TaqMan MGB probes (FAM dye-labeled) were used for detection of the Slc7A2 and Slc7A1 genes, respectively. Predeveloped 18S rRNA (VICdye-labeled probe) TaqMan assay reagent (P/N 4319413E) was used as an endogenous control. The primers were designed to span exon-exon junctions to prevent the detection of genomic DNA. All primers and probe sequences were searched against the Celera database to confirm specificity. The primer and probe sequences for Slc7A2 are as follows: probe, 5Ј-CCCGATGACAAAGTA GCAAT; forward primer, 5Ј-TCAATTCCAAAACGAAGACACCAGTA; and reverse primer, 5Ј-AGGTCAAAAAGAAAGGCCATCACA. An Assay-on-Demand patented by Applied Biosystems (assay Mm00432019_m1) was used to analyze Slc7A1.
In separate tubes, real-time RT-PCR was performed with 80 ng of RNA for both the target genes and endogenous control using a TaqMan one-step RT-PCR master mix reagent kit (P/N 4309169). The cycling parameters for RT-PCR were set as follows: RT, 48°C for 30 min; AmpliTaq activation, 95°C for 10 min; denaturation, 95°C for 15 s; and annealing and/or extension, 60°C for 1 min (repeated 40 times) on ABI7000. Duplicates of the threshold cycle (C T ) values were analyzed in Microsoft Excel using the comparative C T (⌬⌬C T ) method, as described by the manufacturer (Applied Biosystems). The amount of target (2 Ϫ⌬⌬CT ) was obtained and normalized to an endogenous reference (18s rRNA) and a calibrator (one of the experimental samples).
Arginase activity assays. The arginase activities from M cell lysates were measured as previously described (8), with some modifications. Briefly, pMs (10 5 /well, in 96-well plates) were treated with cytokines for 4 h prior to infection with amastigotes at a 2:1 parasite/cell ratio. After removal of the culture supernatants, the cells were washed and incubated with 50 l of 0.1% Triton X-100 containing a protease inhibitor cocktail (Sigma) for 30 min at room temperature. Arginase was activated with 50 l of 10 mM MnCl 2 and 50 mM Tris-HCl (pH 7.5) at 55°C for 10 min. After 25 l of each sample was transferred into a 96-deep-well assay plate, the enzyme reaction was carried out by adding 25 l of 0.5 M of L-arginine (pH 9.7) at 37°C for 60 min with shaking, and the reaction was stopped with 400 l of a H 2 SO 4 -H 3 PO 4 -H 2 O (1:3:7) acid mixture. Subsequently, freshly prepared 9% 1-phenyl-1,2-propanedione-2-oxime (ISPF; Sigma) in 100% ethanol was added (25 l/well), and the reaction plates were incubated at 95 to 100°C for 45 min for color development. After a 10-min incubation in the dark, 200 l of each sample was transferred to transparent microplates for an absorbance reading at 540 nm. A calibration curve was prepared using urea standards (USB, Cleveland, OH) at concentrations of 1.5 to 30 g.
Arginase activities in live, intact cells were also measured as previously described (3) iNOS assay. At 72 h postinfection, culture supernatants were collected for measurement of the end products from the iNOS pathway. Nitrite was measured by using a nitrate/nitrite colorimetric assay kit (Cayman Chemical, Ann Arbor, MI). Griess reagents were used for color development.
L-Arginine uptake assay. After a 4-h cytokine treatment and subsequent infection with amastigotes for 24 h, L-arginine uptake of infected and control pMs was measured as described previously (39), with some modifications. Briefly, after two washes with 1 ml of prewarmed uptake solution (137 mM NaCl, 5. Data analysis. To evaluate the statistical significance of the difference between experimental groups, statistical analysis (Student t test and one-way and two-way analyses of variance [ANOVA]) was performed on a GraphPad Prism 4.0 program (GraphPad Software, Inc., San Diego, CA). For one-way ANOVA, the Dunnett post test was used to compare treatment groups to the medium controls. The Bonferroni post test was used following two-way ANOVA. The differences between groups were considered significant when the P value was Յ0.05.
RESULTS

IFN-␥ enhanced the growth of lesion-derived and axenic L. amazonensis amastigotes in pMs.
We previously reported that IFN-␥ treatment induced significant growth enhancement of L. amazonensis in Ms infected with lesion-derived amastigotes without altering parasite uptake by the cells (27) . Given that lesion-derived amastigotes may be opsonized with antibodies that can induce alternative activation of Ms (19), we extended our study by using axenic amastigotes that were maintained in vitro in the absence of host cells and antibodies. We found that in a manner similar to that of lesion-derived amastigotes (Fig. 1A) (27) , the number of axenic amastigotes recovered from IFN-␥-treated Ms was significantly increased compared to medium controls (P Ͻ 0.001, Fig. 1B ). Similar results were observed when axenic amastigotes of L. mexicana were used (data not shown). Collectively, these results indicate that IFN-␥-mediated growth enhancement does not require antibody opsonization and is a common phenomenon for amastigotes in the L. mexicana complex. Axenic amastigotes of L. amazonensis were therefore used in the rest of the study. Since IFN-␥ϩLPS cotreatment and IL-4 routinely induce parasite killing and enhanced parasite growth, respectively, these treatments were included in subsequent experiments as positive controls to ensure adequate M activation among independent repeats.
Amastigote infection in the presence of IFN-␥ induced the expression of Slc7A2 and L-arginine uptake. To investigate the involvement of the L-arginine metabolic pathway in IFN-␥-mediated parasite growth enhancement, we first examined the expression of putative transporters for L-arginine, mCATs, via real-time RT-PCR. Since Slc7A2A (encoding CAT-2A) and Slc7A3 (encoding for CAT-3) are known to be only expressed in the brain and hepatocytes, respectively (36), we focused our attention on examining the expression of Slc7A1 (encoding for CAT-1) and Slc7A2 (encoding for CAT-2B in Ms). As shown in Fig. 2A , we found that the expression of Slc7A1 in infected Ms remained low and unaffected by cytokine treatments, confirming that mCAT-1 was not involved in differential M activations. In contrast, the levels of Slc7A2 expression were markedly increased in cells treated with IFN-␥ϩLPS or IL-4 (positive controls). Although the increase in Slc7A2 expression was not as high as those of the positive controls, IFN-␥-treated, parasite-infected cells showed an approximately twofold increase in Slc7A2 expression compared to the medium controls (Fig. 2B) . To examine whether the enhanced expression of mCAT-2B mRNA correlated with an increase in cationic amino acid transport into pMs, we performed L-arginine uptake assays using L- on September 7, 2017 by guest http://iai.asm.org/ Downloaded from (39) . We detected a twofold increase in L-arginine uptake via the y ϩ system in IFN-␥-treated, parasite-infected pMs (Fig.  2C) . As expected, high levels of L-arginine uptake were detected in cells treated with IFN-␥ϩLPS or IL-4 (Fig. 2C) , correlating with their Slc7A2 expressions. Since there were no significant differences in the expression patterns of Slc7A1 and Slc7A2 and L-arginine uptake in infected and uninfected cells (data not shown), it appeared that parasite infection alone was insufficient to induce L-arginine transport via mCAT-2B. Together, these data demonstrate that infection by L. amazonensis amastigotes in the presence of IFN-␥ significantly increased mCAT-2B expression and cellular L-arginine transport.
L-Arginine was involved in IFN-␥-mediated growth of L. amazonensis amastigotes. To assess the biological relevance of enhanced Slc7A2 expression in IFN-␥-treated, infected pMs, we directly examined the involvement of L-arginine in IFN-␥-mediated parasite growth enhancement. Since L-NMMA, a nonmetabolized L-arginine analogue, has been shown to effectively block L-arginine transport (2), we treated Ms with this compound in order to examine parasite growth in the absence of L-arginine transport. As shown in Fig. 3A , the addition of L-NMMA abolished IFN-␥-mediated growth enhancement in a dose-dependent manner with a minimum dose of 5 mM required for growth inhibition. L-NMMA also abrogated the effect of L-arginine-mediated parasite killing via IFN-␥ϩLPS and parasite growth enhancement by IL-4 ( Fig. 3B) , indicating the requirement of L-arginine substrate in both of these pathways. Although L-NMMA can effectively block L-arginine transport, it also functions as a direct inhibitor of iNOS. To further verify whether blockade of L-arginine transport can alter parasite infection, we also examined parasite growth in the presence of another L-arginine analogue, L-SDMA, which can compete with L-arginine transport but does not directly block enzymatic activity of iNOS (6) . Similar to the observations with L-NMMA, the addition of L-SDMA inhibited IFN-␥-mediated parasite growth enhancement, as judged by parasite burdens (black bars in Fig. 3C ). To further examine the role of L-arginine, we next tested whether excessive amounts of L-arginine would further enhance parasite growth. As shown in Fig. 3D , 10 mM L-arginine significantly increased parasite burdens in the presence or absence of IFN-␥, suggesting a direct correlation between L-arginine availability and parasite growth. As expected, L-arginine also enhanced parasite killing after IFN-␥ϩLPS treatment, as well as parasite growth enhancement after IL-4 treatment. These data suggest that there is a direct correlation between L-arginine availability and the increase in parasite growth in IFN-␥-treated Ms.
mCAT-2B regulated IFN-␥-mediated growth of L. amazonensis amastigotes. To further verify that L-arginine transport via mCAT-2B was required in IFN-␥-mediated parasite growth, we infected pMs derived from CAT-2 KO and wildtype C57BL/6 mice with L. amazonensis amastigotes, and parasite burdens were measured. In contrast to the wild-type counterparts that contained differential levels of parasite burdens after different cytokine treatments, pMs from CAT-2 KO mice contained comparable parasite burdens in all treatment groups (Fig. 4A) . These results indicated that the effects of IFN-␥-and IL-4-mediated parasite growth enhancement, as well as IFN-␥ϩLPS-mediated parasite killing, were all regulated by mCAT-2B. Consistent with a previous report (39) , the nitrite levels in IFN-␥ϩLPS-treated CAT-2 KO cells were significantly reduced, indicating a complete absence of mCAT-2B (data not shown). A close examination of parasite numbers per cell revealed that 18% of IFN-␥-treated Ms from wild-type (Fig. 4B) , suggesting that the enhanced parasite growth could not be established in the absence of mCAT-2B. This reduction in parasite burdens was not due to a decrease in the susceptibility of Ms from CAT-2 KO mice, as indicated by similar infection rates in all tested groups (Fig. 4C) . Together, these data suggest that L-arginine transport via mCAT-2B plays a significant role in the enhancement of parasite growth in IFN-␥-treated cells.
IFN-␥-mediated treatment was insufficient to activate either iNOS or arginase in infected Ms.
Having demonstrated that IFN-␥ treatment enhanced the expression of Slc7A2 and uptake of L-arginine in amastigote-infected Ms, we then investigated the potential utilization of L-arginine of infected Ms under different stimulations. Since L-arginine is a shared substrate for both iNOS and arginase enzymes, we examined the activities of both enzymes. iNOS induction, as indicated by nitrite production at 72 h postinfection, was markedly upregulated by IFN-␥ϩLPS treatment (P Ͻ 0.01); however, treatment with IFN-␥ alone did not induce any measurable iNOS activity above the basal levels (Fig. 5A) . It is important to note that parasite infection alone also did not induce any measurable nitrite under these experimental settings (data not shown).
We next examined arginase expression by providing substrate and cofactors of the enzymes and measuring the subsequent urea production in cell lysates. As expected, IL-4-treated, amastigote-infected Ms showed a dramatic increase in arginase expression at 16 and 24 h postinfection (Fig. 5B) ; however, basal levels of arginase were observed in untreated cells, as well as in cells pretreated with IFN-␥ or IFN-␥ϩLPS (Fig. 5B) . The arginase activity in live, intact cells was also determined. Using 14 C-L-[guanido]arginine, the release of [ 14 C]urea was measured and percentage of L-arginine conversion by arginase was calculated (3). As shown in Fig. 5C , arginase-mediated L-arginine conversion was significantly increased in IL-4-treated Ms, whereas the conversion rates in IFN-␥-or IFN-␥ϩLPS-treated cells remained comparable to that of medium controls. Collectively, these data suggest that although IFN-␥ treatment can enhance Slc7A2 expression and the uptake of L-arginine of amastigote-infected Ms, it did not significantly induce iNOS or arginase activities. Therefore, the mechanisms of IFN-␥-mediated growth enhancement of L. amazonensis amastigotes appeared to be independent of these two enzymatic activities.
Full activation of the iNOS pathway for effective amastigote killing was dependent on L-arginine availability. To better understand how L-arginine availability influences the fate of L. amazonensis amastigotes within infected Ms, we examined the relationship between L-arginine uptake (Fig. 6A) , nitrite concentrations (Fig. 6B) , and the parasite burdens (Fig. 6C) . on September 7, 2017 by guest http://iai.asm.org/
We found that when 1 ng of LPS/ml was added together with 20 ng of IFN-␥/ml, parasite growth enhancement was still observed, suggesting that low levels of LPS were insufficient to reverse the parasite growth enhancement mediated by IFN-␥. A complete reversal of parasite growth enhancement and the establishment of effective parasite killing was not achieved until sufficiently high levels of LPS were added (Ն10 ng/ml), which correlated with a nitrite level of Ն65 M. Therefore, while an optimal activation of Ms could be achieved for effective control of L. amazonensis amastigotes, suboptimal stimulation of Ms actually promoted parasite survival and growth. Our data provided evidence for a direct correlation between L-arginine uptake and the iNOS activity needed for parasite killing, indicating a fine balance between parasite growth enhancement when cells were treated with IFN-␥ alone, and parasite killing when IFN-␥ was given together with LPS.
DISCUSSION
Since IFN-␥ is one of the major cytokines consistently detected in nonhealing lesions caused by L. amazonensis infection (28), a better understanding of its involvement in immunopathogenesis would provide valuable insight into the requirements for design of vaccines and treatments against New World cutaneous leishmaniasis. Leishmania amastigotes live and multiply within the parasitophorous vacuoles (PVs) of infected Ms. The fate of the parasite depends largely on the activation status of host cells. While IFN-␥ coupled with LPS induces parasite killing via the iNOS pathway (14) , IL-4 promotes parasite growth via the arginase-dependent, alternative activation of Ms (17, 38) . Consistent with our previous report (27) , we showed here that IFN-␥ alone not only failed to activate Ms to kill parasites but actually enhanced the growth of L. amazonensis amastigotes, regardless whether they were isolated from lesions or axenically cultured in vitro (Fig. 1) .
Since L-arginine is a crucial substrate for both iNOS and arginase, we focused our investigation of IFN-␥-mediated parasite growth enhancement on L-arginine transport and L-arginine metabolic pathways. Examination of L-arginine catabolism and its transport provided evidence suggesting that various cytokine stimulations can lead to differential cell activations. As illustrated in Fig. 7 , our working models may explain the influence of cytokine stimulation on L-arginine avail- (Fig. 3) . IFN-␥ alone, therefore, exerts a unique M activation status that was independent of iNOS and arginase.
In the present study, we demonstrated that both IFN-␥ and IL-4 treatments induced L. amazonensis amastigote growth via L-arginine-dependent pathways ( Fig. 3 and 4) . However, the underlying mechanisms of IFN-␥-mediated parasite growth enhancement appeared to be different from that of IL-4. While IL-4 is known to promote parasite growth via the induction of arginase (16), IFN-␥-mediated growth enhancement was not linked to arginase upregulation (Fig. 5C) . Moreover, IFN-␥ and IL-4 could induce parasite growth enhancement to similar extents, although L-arginine transport was moderately induced by IFN-␥ in comparison to IL-4 (Fig. 2C) . These findings suggest that L-arginine-mediated parasite growth enhancement may operate through various mechanisms, either dependent on (18) and produce significant amounts of urea, a product of L-arginine conversion by arginase (40) . Moreover, the presence of arginase enzyme was documented in several species of Leishmania, including L. major, L. amazonensis, and L. mexicana (9) . Finally, targeted deletion of parasite-derived arginase was subsequently shown to inhibit parasite growth both in vitro and in vivo (30) . Collectively, these reports suggest that Leishmania may have an ability to gain access to intracellular L-arginine pool while residing within the host Ms. Since amastigotes reside within specialized, acidic subcellular PVs, it would be valuable to further identify the mechanisms by which L-arginine is transported across the PV membranes. Although mCAT2-B is predominantly expressed on the plasma membranes of Ms (7), it may potentially be recruited to the PVs and facilitate cationic amino acid transport to the parasites. The recruitment of proteins normally expressed on plasma membranes to PVs has been previously reported. For example, major histocompatibility complex class II molecules are known to be present on 90% of the PVs of Leishmania-infected Ms (1, 22) . We are currently investigating whether mCAT-2B is recruited to the PVs and facilitates L-arginine transport for parasite replication. L-Arginine plays an important role in iNOS-mediated control of intracellular pathogens. Conversely, L-arginine conversion to L-ornithine and urea and its involvement in polyamine synthesis has also been shown to promote growth of many pathogens, including Leishmania spp. (21, 30) , Trypanosoma spp. (26) , Helicobacter pylori (4), and Mycobacterium bovis (33) . Similar to our study showing the association of L-arginine transport and the enhancement of L. amazonensis growth, previous studies have demonstrated that other pathogens also interfere with the L-arginine metabolic pathways to promote their survival within the host. For example, the improved survival capacity of AS-1 strain M. bovis BCG was found to be associated with its ability to induce mCAT-2A, mCAT-2B, L-arginine uptake, and arginase activity (33) . Moreover, the ability of the lumen-dwelling protozoon, Giardia lamblia, to take up extracellular L-arginine and compete with iNOS for L-arginine substrate was suggested to be its strategy to evade host defense (11) . Together, these studies strongly suggest that L-arginine metabolic pathways are likely targets for microbial virulence factors and that invasion of these pathways by microorganisms would directly promote their survival within the host.
L. amazonensis infection in mice displays distinct phenotypes compared to infection caused by L. major. While many inbred strains of mice display self-healing phenotypes after L. major infection (29) , L. amazonensis infection results in the development of chronic, nonhealing lesions in most strains of mice (28) . Several intrinsic, parasite-derived factors may contribute to the nonhealing phenotype of L. amazonensis infection. For example, IFN-␥ treatment alone promotes growth, rather than killing, of L. amazonensis amastigotes (27) . We also demonstrated here that L. amazonensis amastigotes are able to survive moderate M activation, and high NO levels are required to trigger sufficient parasite killing (Fig. 6) . Finally, since L. amazonensis infection does not trigger Ms to produce TNF-␣, a cytokine shown to act synergistically with IFN-␥ to efficiently control L. major infection (12) , there may be incomplete activation of the iNOS pathway during L. amazonensis infection. Therefore, the differential requirement for the induction of high iNOS activity for the killing of L. amazonensis may partially explain the general susceptibility of inbred strains of mice to L. amazonensis infection.
In summary, this study provides strong evidence that IFN-␥ alone can induce a unique activation status in L. amazonensisinfected Ms, a process that appears to use L-arginine as a key regulator to promote the growth of intracellular parasites. We also demonstrated a fine balance between host iNOS, arginase, and L-arginine transport via mCAT-2B, as well as their influences on the fate of intracellular parasites. This report highlights the importance of an optimal activation of the host immune system for effective parasite killing and potential challenges in the development of effective vaccines and treatment regimens for the control of New World cutaneous leishmaniasis.
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